256 related articles for article (PubMed ID: 19477171)
1. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
Oshibuchi H; Inada K; Sugawara H; Ishigooka J
Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171
[TBL] [Abstract][Full Text] [Related]
2. [Action of amygdala dopamine and effect of antipsychotics].
Oshibuchi H; Inada K; Ishigooka J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):93-9. PubMed ID: 20491283
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol.
Kawano M; Oshibuchi H; Kawano T; Muraoka H; Tsutsumi T; Yamada M; Inada K; Ishigooka J
Eur J Pharmacol; 2016 Jun; 781():148-56. PubMed ID: 27085900
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid inhibits excess dopamine release in response to a fear-conditioned stimulus in the basolateral complex of the amygdala of methamphetamine-sensitized rats.
Miyagi J; Oshibuchi H; Kasai A; Inada K; Ishigooka J
Eur J Pharmacol; 2014 May; 730():20-5. PubMed ID: 24583338
[TBL] [Abstract][Full Text] [Related]
6. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
8. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
9. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of delayed release of dopamine in the amygdala induced by conditioned fear stress in methamphetamine-sensitized rats.
Suzuki T; Ishigooka J; Watanabe S; Miyaoka H
Eur J Pharmacol; 2002 Jan; 435(1):59-65. PubMed ID: 11790378
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Leite JV; Guimarães FS; Moreira FA
Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine.
Futamura T; Akiyama S; Sugino H; Forbes A; McQuade RD; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1115-9. PubMed ID: 20561555
[TBL] [Abstract][Full Text] [Related]
13. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
Bergman J
Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A
Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992
[TBL] [Abstract][Full Text] [Related]
15. Escitalopram attenuates fear stress-induced increase in amygdalar dopamine following methamphetamine-induced sensitisation: Implications of fine-tuning action of selective serotonin reuptake inhibitors on emotional processing.
Muraoka H; Oshibuchi H; Kawano M; Kawano T; Tsutsumi T; Yamada M; Ishigooka J; Nishimura K; Inada K
Eur J Pharmacol; 2018 Sep; 834():1-9. PubMed ID: 29981749
[TBL] [Abstract][Full Text] [Related]
16. Diazepam suppresses the stress-induced dopaminergic release in the amygdala of methamphetamine-sensitized rat.
Kawano T; Oshibuchi H; Kawano M; Muraoka H; Tsutsumi T; Yamada M; Ishigooka J; Nishimura K; Inada K
Eur J Pharmacol; 2018 Aug; 833():247-254. PubMed ID: 29885289
[TBL] [Abstract][Full Text] [Related]
17. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and rat mesencephalic cultures: Implication of inhibition of vesicular transport.
Matsuo T; Izumi Y; Wakita S; Kume T; Takada-Takatori Y; Sawada H; Akaike A
Eur J Pharmacol; 2010 Aug; 640(1-3):68-74. PubMed ID: 20460122
[TBL] [Abstract][Full Text] [Related]
19. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
20. Amygdalic levels of dopamine and serotonin rise upon exposure to conditioned fear stress without elevation of glutamate.
Yokoyama M; Suzuki E; Sato T; Maruta S; Watanabe S; Miyaoka H
Neurosci Lett; 2005 Apr; 379(1):37-41. PubMed ID: 15814195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
